Thank you to all our Scientific/Medical Advisory Committee members for sharing their time and expertise with us to direct the path of our research program in order to find new treatments and a cure for PSC.
Dr. David Assis
Dr. Assis is an Assistant Professor of Medicine, Section of Digestive Diseases, Medicine Department at the Yale University School of Medicine. He received his M.D. from Jefferson Medical College followed by internship and residency at Thomas Jefferson University Hospital in Philadelphia, where he was also Chief Resident. He completed training in gastroenterology and hepatology followed by transplant hepatology fellowships at Yale University. His clinical and research interests are in autoimmune liver diseases. Specifically, he focuses on autoimmune hepatitis and primary sclerosing cholangitis through both clinical work and translational and basic research using patient bio specimens and animal models. He currently holds a NIH K08 career development award focusing on translational approaches to autoimmune hepatitis. Dr. Assis is vice-chair of the Special Interest Group (SIG) on Cholestatic and Biliary Diseases of the American Association for the Study of Liver Disease (AALSD), and is a co-leader of the clinical trials working group of the International PSC Study Group. He also serves on the Connecticut Board of the American Liver Foundation.
Dr. Dennis Black
Dr. Dennis Black, a pediatric hepatologist, is the James Dustin Buckman Professor of Pediatrics and Professor of Physiology at the University of Tennessee Health Science Center, Memphis. Dr. Black serves as Director of the Children’s Foundation Research Center of Memphis, as well as Vice President for Research for Le Bonheur Children’s Medical Center and Associate Director of the UTHSC Clinical and Translational Science Institute. His research and clinical interests are neonatal lipid metabolism and pediatric liver disease and transplantation. He is Associate Director of the Musette and Allen Morgan, Jr. Foundation for the Study of PSC and Study Chair for the STOPSC multicenter consortium. He has had continuous NIH research funding for the past 18 years. He has served on several grant review committees, including those for the NIH, American Liver Foundation, NASPGHAN, and the American Heart Association. He served as a member of the Editorial Board of the American Journal of Physiology: GI and Liver Physiology from 2003 to 2009.
Dr. Christopher L. Bowlus (Co-chair)
Christopher L. Bowlus is Professor and Chief of the Division of Gastroenterology and Hepatology at the University of California Davis School of Medicine. Dr. Bowlus completed his undergraduate education at the University of California San Diego and received his medical degree from St. Louis University. After completing his Internal Medicine training at UC Davis in 1993, he went on to Fellowship training in Gastroenterology and Hepatology at Yale University. There he worked on the Human Genome Project with particular emphasis on cloning genes in the region of the hemochromatosis gene. In 1998 he returned to UC Davis as an Assistant Professor and established himself as an international expert in autoimmune liver diseases, specifically primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC). Dr. Bowlus has an active research program that focuses on 3 main areas: 1) elucidating the underlying genetic and immunologic causes of PBC and PSC; 2) developing new treatments for PBC and PSC; and 3) improving testing and care of Asian Americans with chronic hepatitis B through the use of community outreach and personalized medicine. His research is funded by the National Institutes of Health, Center for Disease Control and Prevention, and industry sponsors. A respected educator, Dr. Bowlus served as the Gastroenterology Fellowship Program Director at UC Davis for over a decade and is the recipient of the Walter Trudeau Excellence in Teaching Award. Dr. Bowlus is a Fellow of the American College of Physicians, the American Gastroenterology Association, and the American Association for the Study of Liver Disease.
Dr. John Eaton
Dr. John Eaton is an Assistant Professor of Medicine and Transplant Hepatologist at Mayo Clinic in Rochester, Minnesota. Dr. Eaton completed his internal medicine residency training, Chief Medical residency, Gastroenterology & Hepatology fellowship and an advanced Liver transplant fellowship at Mayo Clinic in Rochester, Minnesota. Dr. Eaton also designed and completed a unique 1 year training program that enabled him to focus on cholestatic liver diseases and cholangiocarcinoma prior to joining the staff at Mayo Clinic in Rochester, Minnesota. Dr. Eaton’s clinical efforts are focused on seeing patients with PSC, PBC and cholangiocarcinoma. His research focuses on clinical trials, advanced imaging studies and improving our understanding of the natural history of PSC and methods to predict key outcomes.
Dr. Bertus Eksteen
Dr. Eksteen is Associate Professor of Medicine at the University of Calgary and a transplant hepatologist based at the Foothills Medical Centre in Calgary. He was born in South Africa where he completed his basic medical degree before moving to Birmingham in the UK in 1996 where he completed his training in gastroenterology and transplant hepatology. He was elected a Fellow of the Royal College of Physicians of London, UK in 2011. He spent 10 years on the Birmingham liver transplant unit before moving to the University of Calgary in 2011. His main interests are liver transplantation and autoimmune liver diseases such as Primary Sclerosing Cholangitis (PSC). He runs a dedicated multidisciplinary PSC clinic at the Unversity of Calgary Medical Clinics (UCMC) which provides state of the art care for patients from southern Alberta, western Saskatchewan and eastern British Columbia. The clinic is closely aligned with his PSC research program which aims to evaluate new medications for PSC, novel imaging of the colon and bile ducts and the genetics of PSC.
Dr. Greg Everson
Dr. Greg Everson received his MD degree from Cornell Medical College, NY, and is currently Professor of Medicine and Director of Hepatology at the University of Colorado, Denver. Dr. Everson has published over 300 original papers, books, and book chapters in peer-reviewed journals that include Hepatology, Clinics in Liver Disease, Gastroenterology, Journal of Hepatology, New England Journal of Medicine, The American Journal of Gastroenterology, Alimentary Pharmacology and Therapeutics, and Expert Reviews in Gastroenterology and Hepatology. In conjunction with Hedy Weinberg, he has co-authored 5 editions of the popular “self-help” book, Living with Hepatitis C: A Survivor’s Guide, for patients and families. He is an invited speaker and has presented his work at clinical and scientific meetings nationally and internationally. He is a principal investigator for both the HALT-C trial (Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis) and the A2ALL study (Adult-to-Adult Living Donor Liver Transplantation study) for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH), and numerous other clinical trials. Dr. Everson is a member of the American Association for the Study of Liver Diseases (AASLD), the American Society of Transplantation, the International Liver Transplant Society, and the International Association for the Study of the Liver. In addition, he is a member of both the Transplant Hepatology Committee of the American Board of Internal Medicine, and the standing panel for accreditation appeals in the specialty of Internal Medicine/Transplant Hepatology of the Accreditation Council for Graduate Medical Education. He became involved with PSC Partners because Ricky and Don Safer convinced him that the foundation would become a reality and help patients and families.
Dr. Everson is also an honorary member of our Board of Directors.
Dr. Richard Green (Co-chair)
Dr. Richard Green is a Professor of Medicine and Chief of the Section of Hepatology at Northwestern University Feinberg School of Medicine. He graduated with an undergraduate degree from Duke University and subsequently graduated from the Duke University Medical School with a degree in Medicine. He undertook his Internal Medicine training at Northwestern University, where he also served as the Chief Medical Resident. His Gastroenterology and Hepatology Fellowship training was at Brigham and Women’s Hospital at Harvard Medical School, Boston, MA. He subsequently served as an Instructor of Medicine at Brigham and Women’s Hospital and Harvard Medical School, and as an Assistant Professor of Medicine at the University of Illinois in Chicago.
Dr. Green has been actively involved in clinical and basic investigations of cholestatic liver disease, metabolic liver diseases and fatty liver disorders. His current research efforts focus on the genetics and molecular mechanisms of cholestatic and fatty liver disorders. He is the former Chair of the Cholestatic Liver Disorders Special Interest Group (SIG) of the American Association for the Study of Liver Diseases (AASLD), and the former Chair of the Liver-Biliary Council of the American Gastroenterological Association. He also served as an Associate Editor for the journal Hepatology from 2001-2006. He has authored over 50 original articles, book chapters and reviews on a wide range of hepatic disorders.
Dr. Denise M. Harnois
Dr. Denise Harnois received her medical degree from the medical school at Philadelphia College of Osteopathic Medicine, and then received Internal Medicine training at Thomas Jefferson University Hospital. After completing a fellowship in Hepatology and Transplant Medicine at Mayo Clinic, she joined the staff at Mayo Clinic Florida in 1998. Dr. Harnois is board certified in Transplant Hepatology and Gastroenterology and focuses her interest in the areas of cholestatic liver diseases (including primary sclerosing cholangitis) and hepatobiliary malignancies. She has been a well-recognized resource for patients and physicians in her region through her efforts in outreach and academic work in these areas.
Dr. Gideon Hirschfield
Dr. Gideon Hirschfield is a Senior Lecturer at the Centre for Liver Research, University of Birmingham, UK. He trained in the UK where he studied first at Oxford and then at Cambridge University. He has a PhD from the University of London, and completed his Gastroenterology and Hepatology training predominantly while working on the Liver Transplant Program, Addenbrooke`s Hospital, Cambridge. In addition to being a General Transplant Hepatologist, he has a particular interest in autoimmune liver disease and cholestasis, including PSC. His area of research focuses on the development of new treatments for patients, and understanding the basic mechanisms of disease.
Dr. Johannes R. Hov
Dr. Johannes R. Hov is a researcher at the Norwegian PSC Research Center as well as resident in gastroenterology in the Division of Cancer, Surgery and Transplantation, Oslo University Hospital, Rikshospitalet. He received his MD from the University of Oslo in 2003 and a PhD in 2011 with the thesis “Functional genetics in primary sclerosing cholangitis: Studies of the bile acid receptor TGR5 and genes in the HLA complex”.
He is leading the research group “Genomics and metagenomics in inflammatory diseases” (www.ous-research.no/hov) and the main current research focus is the role of gut microbiota in PSC and other inflammatory conditions with gastrointestinal manifestations, in addition to studies of immunogenetics and biomarkers in PSC.
Dr. Keith Lindor
Dr. Keith Lindor is executive vice provost and dean of the College of Health Solutions at Arizona State University (ASU). He focuses on means for improving population health, while lowering costs and enhancing access.
Dr. Lindor joined ASU in January 2012. Before coming to ASU, he served as dean of the Mayo Medical School and was a professor of medicine and chair in the Division of Gastroenterology and Hepatology. He also served as editor-in-chief of Hepatology and was previously the senior associate editor for Clinical Gastroenterology and Hepatology.
Dr. Lindor’s clinical interests include: cholestatic liver diseases in adults, particularly primary biliary cirrhosis and primary sclerosing cholangitis as well as nonalcoholic steatohepatitis.
He received a bachelor’s of chemistry degree from the University of Minnesota and medical degree from Mayo Medical School. He completed his residency in internal medicine at Bowman Grey School of Medicine at Wake Forest University and his gastroenterology fellowship at the Mayo Clinic.
Dr. Stephen Miller
Dr. Stephen Miller graduated magna cum laude with a BS in mathematics from UNISA in South Africa, and summa cum laude with an MD from the University of The Witwatersrand, Johannesburg, South Africa. Dr. Miller completed his residency and completed his board certification in Internal Medicine from Northwestern University, Chicago, IL, and received his fellowship in Clinical Pharmacology from Chicago Medical School. Dr. Miller served as Attending Physician at VA Hospital, North Chicago, Illinois, and Associate Professor, Clinical Medicine and Pharmacology, at Chicago Medical School. Dr. Miller then served as Executive Director, R&D; Senior Director, International Marketing Operations; and Senior Director, International Business Operations and Pharmaceutical Discovery for GD Searle, Inc. in Chicago, IL. Dr. Miller then co-founded and served as Chief Medical Officer of Atlantic Pharmaceuticals, a biotechnology company listed on NASDAQ, until its private acquisition in 2000. Today, Dr. Miller has a tertiary concierge medicine practice and a private equity business (health care infrastructure and services; quantitative securities operations).
Dr. Cyriel Ponsioen
Cyriel Ponsioen was trained as Internist at the Free University Medical Center in Amsterdam from 1989 to 1995. Thereafter he trained as gastroenterologist at the Academic Medical Center (AMC) in Amsterdam from 1995 till 1998. In 2000 he defended his doctoral thesis on Etiological and Clinical Studies in Primary Sclerosing Cholangitis. From 2000-2006 he worked as consultant gastroenterologist in a large teaching hospital. In 2007 he was appointed senior staff member at the Department of Gastroenterology & Hepatology at the AMC. The focus of his clinical as well as research activities lie in inflammatory bowel disease (IBD) and primary sclerosing cholangitis (PSC). The former mainly focuses on microbiota research in IBD. As for PSC, he has built up a research line in epidemiology, disease course, and biomarkers, and he leads a research line looking into the relationship between the gut and the biliary tree. He is currently PI of 4 international research projects in PSC including the DILSTENT trial, a randomized trial comparing balloon dilatation versus short-term stenting for dominant strictures in PSC. Within the international PSC Study Group he currently chairs the Clinical Working Group.
Dr. James Tabibian
Dr. Tabibian is an Associate Professor of Medicine at the David Geffen School of Medicine in Los Angeles, CA. His clinical and research interests focus on clinico-translational aspects of gastrointestinal and pancreatobiliary endoscopy and, in particular, how they relate to hepatobiliary disorders, especially primary sclerosing cholangitis (PSC). The overarching goal of his endeavors is centered around elucidating molecular underpinnings, novel biomarkers and diagnostics, and therapies. In addition, he is keenly interested in patient-centered outcomes (e.g. preserving health-related quality of life), promoting diversity and mentorship in medicine, and training the next generation of Gastroenterologists.
Dr. Tabibian grew up in Central California, where he attended UC Davis as an undergraduate majoring in International Relations. He received his M.D. degree at the David Geffen School of Medicine at UCLA, where he graduated with Alpha Omega Alpha honors. He then completed Internal Medicine training in the Osler Medical Housestaff Program at Johns Hopkins. Thereafter, James became the first joint NIH T32 track/ABIM Subspecialty Research Pathway fellow in the Division of Gastroenterology and Hepatology at Mayo Clinic Rochester, and while completing his Gastroenterology training, he successfully defended his PhD thesis entitled, “Etiopathogenesis, modeling, and treatment of primary sclerosing cholangitis (PSC)” through Mayo Graduate School, Center for Clinical and Translational Studies (CTSA), under the mentorship of Drs. Nicholas F. LaRusso and Keith D. Lindor. In addition, Dr. Tabibian was a Co-Principle Investigator of the 2013 PSC Partners Seeking a Cure Annual Research Grant and the 2014 AASLD Clinical and Translational Research Award for his proposals related to translational PSC research.
Following his training at Mayo Clinic, Dr. Tabibian joined the University of Pennsylvania as an Instructor and Advanced Endoscopy Fellow. Here he spent a year learning specialized techniques such as ERCP, EUS-FNA, and cholangioscopy, teaching endoscopy to Gastroenterology fellows, and attending on hospital wards. At the terminus of his year at Penn, Dr. Tabibian moved back to California to join the esteemed faculty at UC Davis Medical Center as an Assistant Professor and Director of Fellow Research. While he remains involved in research endeavors at UC Davis, Dr. Tabibian was recruited in 2017 to become the Director of Endoscopy and Resident Research Director at Olive View-UCLA Medical Center, where he continues his clinical, research, and teaching activities.